Tvardi Q2 FY26 net loss turns to USD 6.5 million

Reuters2026/08/14 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tvardi Therapeutics posted a Q2 net loss of USD 6.5 million, swinging from net income of USD 4.2 million a year earlier.
Loss per share was USD 0.69, versus basic EPS of USD 0.51 in the prior-year quarter.
R&D expense fell 31.09% to USD 4 million, on lower TTI-101 clinical costs, partly offset by higher TTI-109 development spending.
G&A costs slipped 14.26% to USD 2.63 million, on lower professional fees, partly offset by higher legal and investor relations costs.
Cash, cash equivalents and short-term investments totaled USD 15.8 million; runway forecast through the HCC topline readout into Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140700PRIMZONEFULLFEED9809790) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tvardi Q2 FY26 net loss turns to USD 6.5 million

You may also like

Crypto prices